Please use this identifier to cite or link to this item:
Title: Prospective analysis of circulating metabolites and breast cancer in EPIC
Author: His, Mathilde
Viallon, Vivian
Dossus, Laure
Gicquiau, Audrey
Achaintre, David
Scalbert, Augustin
Ferrari, Pietro
Romieu, Isabelle
Onland-Moret, N. Charlotte
Weiderpass, Elisabete
Dahm, Christina C.
Overvad, Kim
Olsen, Anja
Tjønneland, Anne
Fournier, Agnès
Rothwell, Joseph A.
Severi, Gianluca
Kühn, Tilman
Fortner, Renée T.
Boeing, Heiner
Trichopoulou, Antonia
Karakatsani, Anna
Martimianaki, Georgia
Masala, Giovanna
Sieri, Sabina
Tumino, Rosario
Vineis, Paolo
Panico, Salvatore
van Gils, Carla H.
Nøst, Therese Haugdahl
Sandanger, Torkjel M.
Skeie, Guri
Quiros, J. Ramón
Agudo, Antonio
Sanchez, Maria Jose
Amiano, Pilar
Huerta Castaño, José María
Ardanaz, Eva
Schmidt, Julie A.
Travis, Ruth C.
Riboli, Elio
Tsilidis, Konstantinos K.
Christakoudi, Sofia
Gunter, Marc J.
Rinaldi, Sabina
Keywords: Càncer de mama
Issue Date: 24-Jan-2019
Publisher: Biomed Central
Abstract: Background: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. Methods: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. Results: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70-0.90), asparagine (OR = 0.83 (0.74-0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76-0.90)), aa C36:3 (OR = 0.84 (0.77-0.93)), ae C34:2 (OR = 0.85 (0.78-0.94)), ae C36:2 (OR = 0.85 (0.78-0.88)), and ae C38:2 (OR = 0.84 (0.76-0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11-1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06-1.24)) and PC ae C36:3 (OR = 0.88 (0.82-0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. Conclusions: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
Note: Reproducció del document publicat a:
It is part of: BMC Medicine, 2019, vol. 17
Related resource:
Appears in Collections:Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
HisM.pdf1.01 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons